SMTI Earnings Prediction
The chart below shows how SMTI performed 10 days before and after its earnings report, based on data from the past quarters. Typically, SMTI sees a +7.49% change in stock price 10 days leading up to the earnings, and a +6.17% change 10 days following the report. On the earnings day itself, the stock moves by -3.36%. This data can give you a slight idea of what to expect for the next quarter's release.
SMTI Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
21.67M
35.24%
7.50%
Gross Margin
85.71%
3.45%
1.37%
Operating Margin
-8.20%
-17.26%
-42.98%
Net Margin
-13.30%
94.73%
-24.04%
EPS
-0.34
-161.54%
-17.07%
No Data Available
SMTI Earnings Analysis
Sanara MedTech Inc. Common Stock Corporation (SMTI.O) Earnings Conference Call
Positive
Record Revenue Achievement: 1. Record Revenue Growth: Sanara MedTech achieved $21.7 million in net revenue for Q3 2024, marking a 35% increase year-over-year and the 12th consecutive record revenue quarter.
Adjusted EBITDA Increase: 2. Improved Adjusted EBITDA: The company generated adjusted EBITDA of $800,000 in Q3 2024, a significant increase from $300,000 in Q3 2023, reflecting improved operational efficiency.
Sales Performance Increase: 3. Strong Sales Performance: Sales of soft tissue products rose from $13.6 million in Q3 2023 to $18.9 million in Q3 2024, while bone fusion product sales increased from $2.3 million to $2.8 million in the same period.
Market Penetration Expansion: 4. Expansion of Market Reach: Sanara's products were sold in over 1,200 hospitals across 34 states, with contracts or approvals in more than 4,000 facilities, demonstrating significant market penetration.
Investment in Oncology Innovation: 5. Strategic Investment in ChemoMouthpiece: The company invested $5 million for a 6.6% ownership in ChemoMouthpiece LLC, aligning with its wound and skin care strategy and enhancing its product offerings in the oncology space.
Negative
Net Loss Increase: 1. Increased Net Loss: Sanara reported a net loss of $2.9 million for Q3 2024, worsening from a net loss of $1.1 million in Q3 2023.
Negative EBITDA in Tissue Health: 2. Negative Segment EBITDA: The Tissue Health Plus segment generated a negative EBITDA of $1.7 million in Q3 2024 and a negative $3.4 million year-to-date through September 30, 2024.
Increasing SG&A Costs: 3. Rising SG&A Expenses: SG&A expenses increased to $19 million in Q3 2024, up from $13.9 million in the same quarter of 2023, driven by higher sales and marketing costs.
Increased Interest Expense: 4. Higher Interest Expense: Interest expense rose to $900,000 in Q3 2024, compared to $200,000 in Q3 2023, primarily due to the term loan with CRG.
Cash Burn Risks: 5. Cash Burn Concerns: Despite a cash balance of $16.3 million at the end of Q3 2024, ongoing net losses and increased borrowing raise concerns about future cash burn and profitability timelines.
SMTI FAQs
How does SMTI typically perform around its earnings report dates?
Is Sanara MedTech Inc. (SMTI) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
SMTI Earning Call Sentiment
Sanara MedTech Inc. (SMTI) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
SMTI.O
10.94%Positive
The earnings call presented mixed signals: strong revenue growth (35% YoY), but increased net loss due to higher SG&A and interest expenses. The investment in ChemoMouthpiece and exclusive distribution agreement could be positive, yet management's vague responses in the Q&A raise concerns. The negative EBITDA for the Tissue Health Plus segment and increased interest expenses indicate financial challenges. Overall, while there are positive developments, the uncertainties and financial pressures balance them out, leading to a neutral sentiment.